Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate specific antigen: a useful screening test?

J Concato1

  • 1Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA.

Cancer Journal (Sudbury, Mass.)
|May 10, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

External control arms in oncology: current use and future directions.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Renal artery revascularization in patients with atherosclerotic renal artery stenosis and impaired renal function: conservative management versus renal artery stenting.

Clinical nephrology·2010
Same author

Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review.

Kidney international·2007
Same author

Predicting which patients can resume oral nutrition after percutaneous endoscopic gastrostomy tube placement.

Alimentary pharmacology & therapeutics·2005
Same author

Patient preferences for treatment of rheumatoid arthritis.

Annals of the rheumatic diseases·2004
Same author

Hyperglycaemia in patients with acute ischaemic stroke: how often do we screen for undiagnosed diabetes?

QJM : monthly journal of the Association of Physicians·2003
Same journal

Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Management of Classic Hodgkin Lymphoma in Special Clinical Situations.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Older Patients With Hodgkin Lymphoma: A Contemporary Review.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy.

Cancer journal (Sudbury, Mass.)·2026
See all related articles

Prostate specific antigen (PSA) screening for prostate cancer is debated. While early detection is possible, evidence for reduced mortality is lacking, and screening carries risks. Verbal informed consent is recommended for patient selection.

Area of Science:

  • Urology
  • Oncology
  • Public Health

Background:

  • The use of prostate specific antigen (PSA) for prostate cancer screening is controversial.
  • Proponents highlight early detection of organ-confined disease for potential cure.
  • Opponents cite a lack of evidence for decreased mortality and risks of morbidity and mortality from treatment of non-fatal disease.

Purpose of the Study:

  • To examine the limitations of PSA as a screening test for prostate cancer.
  • To advocate for an approach using verbal informed consent for patient selection in PSA testing.

Main Methods:

  • Review of existing literature and evidence regarding PSA screening.
  • Analysis of the benefits and harms associated with PSA testing and subsequent prostate cancer treatment.

Related Experiment Videos

  • Examination of the ethical considerations in patient selection for screening.

    • Main Results:

    • PSA screening has limitations and does not definitively reduce prostate cancer mortality.
    • Population-based screening can lead to overdiagnosis and overtreatment, causing significant morbidity and mortality.
    • A verbal informed consent process is crucial for identifying appropriate candidates for PSA testing.

    Conclusions:

    • The effectiveness of PSA screening in reducing prostate cancer mortality remains unproven.
    • The potential harms of screening, diagnosis, and treatment must be carefully weighed against benefits.
    • Implementing a verbal informed consent strategy is essential for responsible PSA testing and patient management.